LLY
NYSE · Pharmaceuticals
Eli Lilly and Co.
$1,058.56
+49.04 (+4.86%)
LLY News30 articles
CSL Shares Dip Amid Buyback Activity; Eli Lilly Partnership in Focus
CSL shares retreated 0.6% on Friday, ending a two-day advance. The company reported additional buyback activity and confirmed a new licensing agreement with Eli Lilly.
CSL Gains on Lilly Partnership, Buyback Activity Amid Leadership Shift
CSL Limited's stock advanced following a new drug development pact with Eli Lilly and ongoing share repurchases, while the board searches for a permanent CEO.
CSL Shares Gain on $100M Lilly Kidney Drug Partnership, Buyback Continues
CSL Ltd shares advanced following a $100 million licensing agreement with Eli Lilly for the kidney disease drug clazakizumab. The company also continued its share repurchase program.
Lilly's Retevmo Hits Trial Goal in Early Lung Cancer, Stock Reaction Awaited
Eli Lilly announced positive Phase 3 results for Retevmo in early-stage RET fusion-positive non-small cell lung cancer. U.S. market closure delays stock reaction until Tuesday.
Lilly's $1.5B Oral Obesity Pill Stockpile Signals Major Launch Ambitions
Eli Lilly has accumulated $1.5 billion in pre-launch inventory for its experimental oral obesity treatment orforglipron, with the FDA's target decision date set for April 10. The substantial stockpile highlights the company's push to overcome supply limitations that have hampered the GLP-1 market.
Eli Lilly Builds $1.5B Inventory for Obesity Pill Ahead of FDA Decision
Eli Lilly shares edged higher Friday as the company disclosed a $1.5 billion inventory build for its experimental weight-loss pill orforglipron, awaiting an FDA decision this spring.
Lilly Builds $1.5B Obesity Pill Inventory Ahead of Key FDA Decision
Eli Lilly shares gained as the pharmaceutical giant disclosed a $1.5 billion inventory build for its experimental oral obesity treatment ahead of an anticipated FDA decision in April.
Lilly Gains on China IBD Drug Approval, Oral GLP-1 Race Heats Up
Eli Lilly shares advanced nearly 2% after securing Chinese approval for its inflammatory bowel disease drug mirikizumab. Investors also await a key U.S. decision on the company's oral weight-loss pill expected in April.
Hims & Hers Shares Stabilize After Novo Nordisk Patent Lawsuit Rattles Weight-Loss Strategy
Hims & Hers stock edged up 0.1% premarket following steep declines after Novo Nordisk filed a patent lawsuit over compounded semaglutide. Investors await court developments, FDA signals, and the company's Feb. 23 earnings.
Merck Shares Dip Following Insider Transactions Amid Revenue Forecast Concerns
Merck shares declined 0.5% after SEC filings revealed stock sales by two executives, adding pressure following a revenue outlook that fell short of analyst expectations.
Eli Lilly shares retreat as $2.4B Orna acquisition and China partnership draw scrutiny
Eli Lilly's stock declined 0.9% as investors assessed the company's strategic moves into cell therapy and Chinese drug development. The market is weighing increased pipeline spending against intensifying competition in obesity treatments.
Hims & Hers Shares Plunge 16% After Halting $49 Weight-Loss Pill Amid Novo Nordisk Lawsuit
Hims & Hers Health stock tumbled in after-hours trading following the withdrawal of its compounded semaglutide product and a patent infringement lawsuit from Novo Nordisk. Leerink Partners reduced its price target on the company.
Eli Lilly Shares Dip Following $2.4 Billion Orna Therapeutics Acquisition Announcement
Eli Lilly shares declined 1.3% in after-hours trading after announcing a $2.4 billion acquisition of Orna Therapeutics. Investors are monitoring the deal's impact on Lilly's pipeline and upcoming regulatory decisions.
Novo Nordisk Shares Surge as Hims Abandons Low-Cost Semaglutide Pill
Novo Nordisk stock climbed over 8% after Hims & Hers canceled plans for a $49 compounded weight-loss pill. The move follows FDA warnings against unapproved GLP-1 drug marketing.
Novo Nordisk Rebounds as FDA Vows Crackdown on Wegovy Copycats
Novo Nordisk B shares surged 5.29% after Hims & Hers halted its $49 compounded version of Wegovy, with the FDA pledging action against unauthorized copycats. The stock remains down roughly 20% over five sessions amid pricing uncertainty.
Merck Nears 52-Week Peak Amid Insider Sale, Investors Eye Pipeline Updates
Merck shares climbed 1.8% to $121.93, extending gains for a seventh session and approaching a 52-week high. An executive sold 37,685 shares as investors await the impact of 2026 guidance and pipeline developments.
FDA Crackdown on Compounded Weight-Loss Drugs Boosts Eli Lilly Shares
Eli Lilly's stock rose 3.7% after the FDA warned Hims & Hers to halt sales of a non-approved compounded GLP-1 weight-loss pill, signaling a regulatory clampdown that may support pricing for branded obesity drugs.
Amgen Reaches 52-Week Peak on Friday; Investors Eye Inflation Data and Drug Pricing
Amgen shares surged 4.5% to close at $384.32 on Friday, achieving a new 52-week high. Market participants are monitoring upcoming U.S. inflation figures and developments in drug pricing.
Healthcare Sector Sees Divergence: Molina Plunges on Outlook, XLV Gains Amid Regulatory Warnings
Molina Healthcare plummeted 25.5% after slashing its 2026 profit forecast and announcing a Medicare Part D exit, while the Health Care Select Sector SPDR Fund (XLV) rose 1.8%. Regulatory warnings on compounded obesity drugs added pressure to the sector.
FDA Crackdown on Compounded Weight-Loss Drugs Boosts Eli Lilly Shares
Eli Lilly stock gained 3.7% after FDA signaled action against telehealth firm Hims & Hers over $49 compounded weight-loss alternatives. Regulatory uncertainty continues to impact obesity drug market valuations.
HKEX Earnings Preview: IPO Pipeline and Market Reforms in Focus
HKEX shares edged down 0.24% to HK$407.80 in volatile Friday trading as investors await February 26 earnings. Chairman Carlson Tong reported 488 companies in IPO pipeline with 24 listings raising HK$87 billion so far in 2026.
Alphabet Shares Surge on Tariff Relief and AI Momentum Ahead of Nvidia Report
Alphabet's Class C shares climbed 3.7% to $314.90 in after-hours trading, buoyed by a favorable Supreme Court tariff ruling and a series of AI-related announcements. Investor focus now shifts to Nvidia's upcoming earnings for clues on AI demand.
Telix Soars on Strong Revenue Growth and Upbeat 2026 Forecast
Telix Pharmaceuticals shares jumped 14.2% following the release of its full-year results, which showed a 56% revenue increase to US$803.8 million for 2025 and a forecast for 2026 revenue between US$950 million and US$970 million.
Xero Shares Edge Higher on Melio-Related Share Issuance, Eyes on April Escrow Release
Xero's stock closed up 0.8% at A$80.55 following a disclosure of 61,445 new shares issued for the Melio deal. A larger tranche of 1.32 million shares is set to exit voluntary escrow on April 15, 2026.
Xero Shares Edge Lower on Melio Acquisition Share Issuance Filing
Xero's stock declined following a regulatory filing detailing new shares issued for the Melio acquisition. Investors are monitoring further share releases and the upcoming FY26 results in May.
Uber Targets $1B European Delivery Expansion Amid CFO Transition
Uber Technologies is expanding its Uber Eats service to seven additional European countries, aiming for $1 billion in extra gross bookings over three years. The move comes as the company prepares for a CFO transition and awaits approval for a Türkiye delivery acquisition.
AbbVie Gains Ahead of Holiday; Investors Eye Pipeline and Pricing
AbbVie shares advanced 1.8% to $231.50 in Friday's session, outpacing peers. Trading volume was elevated as investors assess the company's strategic pivot and regulatory challenges.
Rivian Soars 27% on Strong 2026 Delivery Outlook for R2 SUV
Rivian Automotive shares jumped 26.6% to $17.73 following an optimistic 2026 delivery forecast centered on its lower-priced R2 SUV. U.S. markets are closed Monday for Presidents Day.
S&P Global Surges 3% on Insider Purchase, Rate Relief
S&P Global shares gained 3.1% Friday, buoyed by an insider purchase and a decline in Treasury yields following January inflation figures. Trading volume was nearly double the average.
Vertex Shares Surge on Analyst Upgrade, Pipeline Expansion in Focus
Vertex Pharmaceuticals shares climbed 5.7% following an upgrade from Oppenheimer, driven by its 2026 revenue outlook and expanding pipeline in gene-editing, pain, and kidney therapies.